A Novel Polymorphism, ⁷⁰Leu/Phe, Disrupts a Consensus Leu Residue within the Leucine-rich Repeat Sequence of Platelet Glycoprotein Ibα

Summary

Platelet glycoprotein (GP) Ib/IX/V complex mediates high-shear dependent platelet activation through an interaction with the von Willebrand factor (vWF). All four subunits of the complex have a structural motif, the leucine-rich repeat (LRR) sequence, with leucines in conserved positions. Here we report a new polymorphism, Leu/Phe at residue 70 of GPIbα, which disrupts the consensus sequence of the LRR in the vWF binding domain. Genotype frequencies among 142 healthy Japanese subjects were 92.3%, 7.7%, and 0.0%, for the ⁷⁰Leu/Leu, ⁷⁰Leu/Phe, and ⁷⁰Phe/Phe genotypes, respectively.

Ristocetin-induced or shear-induced platelet aggregation was not significantly different between the ⁷⁰Leu/Leu and ⁷⁰Leu/Phe genotypes. In in vitro studies, a recombinant GPIbα fragment with ⁷⁰Phe (L70F) as compared to that with ⁷⁰Leu (WT) had low reactivity to anti-GPIbα monoclonal antibodies, GUR20-5 and Hip1, both of which recognize conformation-specific epitopes within the 45-kDa domain. Ristocetininduced ¹²⁵I-vWF binding to L70F, however, did not differ from that to WT.

Keywords

Polymorphism - platelets - glycoprotein Iba - leucine-rich repeat - genetics

• References

• 1 Lopez JA. The platelet glycoprotein Ib-IX complex. Blood Coagul Fibrinolysis 1994; 05: 97-119.
• 2 Clemetson KJ. Platelet GPIb-V-IX complex. Thromb Haemost 1997; 78: 266-70.
• 3 Ware J. Molecular analyses of the platelet glycoprotein Ib-IX-V receptor. Thromb Haemost 1998; 79: 466-78.
• 4 Ikeda Y, Handa M, Murata M, Goto S. A new approach to antiplatelet therapy: Inhibitor of GPIb/V/IX-vWF interaction. Haemostasis 2000; 30 Collagen: 44-52.
• 5 Berndt MC, Shen Y, Dopheide SM, Gardiner EE, Andrews RK. The vascular biology of the glycoprotein Ib-IX-V complex. Thromb Haemost 2001; 86: 178-88.
• 6 Ikeda Y, Handa M, Kawano K, Kamata T, Murata M, Araki Y, Anbo H, Kawai Y, Watanabe K, Itagaki I, Sakai K, Ruggeri ZM. The role of von Willebrand factor and fibrinogen in platelet aggregation under varying shear stress. J Clin Invest 1991; 87: 1234-420.
• 7 Ikeda Y, Murata M, Goto S. von Willebrand factor-dependent shearinduced platelet aggregation: Basic mechanisms and clinical implications. Ann New York Acad Sci 1997; 323-36.
• 8 Hocking AM, Shinomura T, McQuillan DJ. Leucine-rich repeat glycoproteins of the extracellular matrix. Matrix Biol 1998; 17: 1-19.
• 9 Lopez JA, Andrews RK, Afshar-Kharghan V, Berndt MC. Bernard-Soulier syndrome. Blood 1998; 91: 4397-418.
• 10 Titani K, Takio K, Handa M, Ruggeri ZM. Amino acid sequence of the von Willebrand factor-binding domain of platelet membrane glycoprotein Ib. Proc Natl Acad Sci USA 1987; 84: 5610-4.
• 11 Takahashi H, Murata M, Moriki T, Anbo H, Furukawa T, Nikkuni K, Shibata A, Handa M, Kawai Y, Watanabe K, Ikeda Y. Substitution of Val for Met at residue 239 of platelet glycoprotein Ib alpha in Japanese patients with platelet-type von Willebrand disease. Blood 1995; 85: 727-33.
• 12 Wenger RH, Kieffer AN, Wicki N, Clemetson KJ. Structure of the human platelet membrane glycoprotein Iba gene. Biochem Biophys Res Commun 1988; 156: 389-95.
• 13 Murata M, Fukuyama M, Satoh K, Fujimura Y, Yoshioka A, Takahashi H, Handa M, Kawai Y, Watanabe K, Ikeda Y. Low shear stress can initiate von Willebrand factor-dependent platelet aggregation in patients with type IIB and platelet-type von Willebrand disease. J Clin Invest 1993; 92: 1555-8.
• 14 Murata M, Ware J, Ruggeri ZM. Site-directed mutagenesis of a soluble recombinant fragment of platelet glycoprotein Ib alpha demonstrating negatively charged residues involved in von Willebrand factor binding. J Biol Chem 1991; 266: 15474-80.
• 15 Kawasaki T, Taniuchi Y, Hisamichi N, Fujimura Y, Suzuki M, Titani K, Sakai Y, Kaku S, Satoh N, Takenaka T, Handa M, Sawai Y. Tokaracetin, a new platelet antagonist that binds to platelet glycoprotein Ib and inhibits von Willebrand factor-dependent shear-induced platelet aggregation. Biochem J 1995; 308: 947-53.
• 16 Handa M, Titani K, Holland LZ, Roberts JR, Ruggeri ZM. The von Willebrand factor-binding domain of platelet membrane glycoprotein Ib. Characterization by monoclonal antibodies and partial amino acid sequence analysis of proteolytic fragments. J Biol Chem 1986; 261: 12579-85.
• 17 Vicente V, Kostel PJ, Ruggeri ZM. Isolation and functional characterization of the von Willebrand factor-binding domain located between residues His¹-Arg²⁹³ of the alpha-chain of glycoprotein Ib. J Biol Chem 1988; 263: 18473-9.
• 18 Shen Y, Romo GM, Dong JF, Schade A, McIntire LV, Kenny D, Whisstock JC, Berndt MC, Lopez JA, Andrews RK. Requirement of leucine-rich repeats of glycoprotein (GP) Ib alpha for shear-dependent and static binding of von Willebrand factor to the platelet membrane GP Ib-IX-V complex. Blood 2000; 95: 903-10.
• 19 Fraker PJ, Speck Jr JC. Protein and cell membrane iodinations with a sparingly soluble chloroamide,1,3,4,6-tetrachloro-3a,6a-diphenylglycoluril. Biochem Biophys Res Commun 1978; 80: 849-57.
• 20 Murata M, Russell SR, Ruggeri ZM, Ware J. Expression of the phenotypic abnormality of platelet-type von Willebrand disease in a recombinant glycoprotein Ib alpha fragment. J Clin Invest 1993; 92: 1213-20.
• 21 Moriki T, Murata M, Kitaguchi T, Anbo H, Handa M, Watanabe K, Takahashi H, Ikeda Y. Expression and functional characterization of an abnormal platelet membrane glycoprotein Ib alpha (Met239 → Val) reported in patients with platelet-type von Willebrand disease. Blood 1997; 90: 698-705.
• 22 Miller JL, Lyle VA, Cunningham D. Mutation of leucine-57 to phenylalanine in a platelet glycoprotein Ib alpha leucine tandem repeat occurring in patients with an autosomal dominant variant of Bernard-Soulier disease. Blood 1992; 79: 439-46.
• 23 Kenny D, Jonsson OG, Morateck PA, Montgomery RR. Naturally occurring mutations in glycoprotein Ib alpha that result in defective ligand binding and synthesis of a truncated protein. Blood 1998; 92: 175-83.
• 24 Kobe B. Deisenhofer Crystal structure of porcine ribonuclease inhibitor, a protein with leucine-rich repeats. Nature 1993; 366: 751-6.
• 25 Cauwenberghs N, Vanhoorelbeke K, Vauterin S, Westra DF, Romo G, Huizinga EG, Lopez JA, Berndt MC, Harsfalvi J, Deckmyn H. Epitope mapping of inhibitory antibodies against platelet glycoprotein Ib alpha reveals interaction between the leucine-rich repeat N-terminal and C-terminal flanking domains of glycoprotein Ib alpha. Blood 2001; 98: 652-60.
• 26 Li C, Martin SE, Roth GJ. The genetic defect in two well-studied cases of Bernard-Soulier syndrome: A point mutation in the fifth leucine-rich repeat of platelet glycoprotein Ib alpha. Blood 1995; 86: 3805-14.
• 27 Antonucci JV, Martin ES, Hulick PJ, Joseph A, Martin SE. Bernard-Soulier syndrome: common ancestry in two African American families with the GP Ib alpha Leu¹²⁹Pro mutation. Am J Hematol 2000; 65: 141-8.
• 28 Ware J, Russell SR, Marchese P, Murata M, Mazzucato M, De Marco L, Ruggeri ZM. Point mutation in a leucine-rich repeat of platelet glycoprotein Ib alpha resulting in the Bernard-Soulier syndrome. J Clin Invest 1993; 91: 2133-7.
• 29 Murata M, Furihata K, Ishida F, Russell SR, Ware J, Ruggeri ZM. Genetic and structural characterization of an amino acid dimorphism in glycoprotein Ib alpha involved in platelet transfusion refractoriness. Blood 1992; 79: 3086-90.
• 30 Murata M, Matsubara Y, Kawano K, Zama T, Aoki N, Yoshino H, Watanabe G, Ishikawa K, Ikeda Y. Coronary artery disease and polymorphisms in a receptor mediating shear stress-dependent platelet activation. Circulation 1997; 96: 3281-6.
• 31 Sonoda A, Murata M, Ito D, Tanahashi N, Ohta A, Tada Y, Takeshita E, Yoshida T, Saito I, Yamamoto M, Ikeda Y, Fukuuchi Y, Watanabe K. Association between platelet glycoprotein Ib alpha genotype and ischemic cerebrovascular disease. Stroke 2000; 31: 493-7.
• 32 Bray PF. Platelet glycoprotein polymorphisms as risk factors for thrombosis. Curr Opin Hematol 2000; 07: 284-9.